posting velocity //
Based on 9 events over 90 days. Green days had more opens than closes, red vice-versa. The dark line is the 7-day rolling average.
Loading…
See your match score and the roles you fit best at this company — based on your CV.
Based on Trevo job data
Hiring mostly in QA
Based on 7 jobs with a real publish stamp from the source — not detection time. 0 posted in the last week, 0 in the last month. Hours in Israel timezone.
By day of week
By hour of day
Peak: Mon around 00:00. Keep your CV ready for it.
Showing: Israel. Click another pill to switch.
Open now
2
Total active openings across all sites
Δ 28-day
+1
Opens minus closes in the last 28 days
Δ 90-day
+1
Opens minus closes in the last 90 days
posting velocity //
Based on 9 events over 90 days. Green days had more opens than closes, red vice-versa. The dark line is the 7-day rolling average.
role mix //
The green layer is the current share of active openings by role. The grey dashed layer is the 90-day baseline — gaps between them show where the company is shifting its hiring mix.
seniority pyramid //
Seniority is not exposed by the source for this company.
Distribution of active openings by seniority. The 'unknown' row groups jobs from sources that don't expose seniority.
geography //
Active openings by region. Click a row to see jobs in that area.
time on market //
Median
28.9 days
25th pct
25.9 days
75th pct
29.9 days
Based on 5 closed jobs and 2 still open (right-censored). Curve is Kaplan-Meier; band is the 95% CI.Low event count — the median will stabilise after ~45 more closures. Until then treat the values as indicative.
Window: 180 days back. Don't read the mean — the long tail biases it. Median and percentiles are the honest summary.
Republish rate
—
Fewer than 10 closures in the window — not enough to compute.
267
+7as of 2026-06-28
company intel · ai-generated
Updated 90d ago
Surgical Science is a publicly traded Swedish company (Nasdaq First North Growth Market: SUS) headquartered in Gothenburg. Its significant Israeli presence is the result of acquiring the Israeli company Simbionix from 3D Systems in August 2021 for $305M. Simbionix, originally founded in 1997, now operates as Surgical Science's major R&D center located in Airport City (Lod), Israel.
The company develops virtual reality (VR) simulators for medical and surgical training. The technology allows medical residents and surgeons to practice procedures in a controlled environment using physics-based tissue simulation and anatomical modeling. Operations are divided into two segments: Educational Products sold directly to hospitals and universities, and an Industry/OEM segment where the simulation software is integrated into robotic surgery platforms developed by medical device manufacturers.
The product line, heavily driven by the Israeli Simbionix team, includes the LAP Mentor for laparoscopic surgery, the GI Mentor for gastrointestinal endoscopy, and the RobotiX Mentor for robotic surgery training. These systems combine physical hardware interfaces that mimic actual surgical instruments with proprietary VR software.
Surgical Science competes directly with companies like Mentice and VirtaMed. The 2021 acquisition of Simbionix explicitly expanded Surgical Science's footprint in the medical simulation market, particularly in the robotic surgery and endoscopic simulation sectors.
The Israeli operation in Airport City functions as a primary global R&D hub for the parent company. It houses software engineers, computer graphics developers, 3D artists, and medical specialists. Hiring in Israel typically focuses on C++ development, computational physics, computer graphics, and algorithm design to support the core simulation engine.
key people
Key people for this company are being prepared — they will appear here as soon as available.
Register to get company-tailored interview prep.
hiring signal · from our data
From our job data · always current
2 open roles in Israel
Live openings we track — Israel first, plus worldwide when we have them.
Top roles
news feed
No recent news about this company.